bullish
EuBiologics (206650 KS): Accelerated Double-Digit Sales Growth In 2022; Strong Demand to Continue
314 Views22 Feb 2023 18:51
SUMMARY
- In 2022, Eubiologics (206650 KS) reported revenue growth of 41% YoY to KRW55.47B, driven by increased supply of cholera vaccine to UNICEF following the outbreak of cholera worldwide.
- In 2022, more than 29 countries reported cholera cases or outbreaks, up from 20 countries five year ago. Globally cholera vaccine is in short supply.
- Eubiologic’s vaccine manufacturing capacity is expected to go up to 90 million doses after completion of the expansion project this year, which will drive sustainable sales growth.
Begin exploring Smartkarma's AI-augmented investing intelligence platform with a complimentary Preview Pass to:
- Unlock research summaries
- Follow top, independent analysts
- Receive personalised alerts
- Access Analytics, Events and more
Join 55,000+ investors, including top global asset managers overseeing $13+ trillion.
Upgrade later to our paid plans for full-access.
or
Already have an account? Sign In Now
Discussions
(Paid Plans Only)
Rising
Tina Banerjee
Global Healthcare Analyst
Price Chart(Sign Up to Access)
- EuBiologics (206650 KS): Secular Sectoral Tailwind Is Not The Only Catalyst15 Apr 2024
- EuBiologics (206650 KS): Solid 1H23 Performance; Oral Cholera Vaccine on A Consistent Growth Path09 Sep 2023
- EuBiologics (206650 KS): Capacity Expansion Amid Global Supply Shortage to Accelerate Growth23 May 2023
- EuBiologics (206650 KS): Base Business Recovery; COVID Vaccine Undergoing Phase 3 Trial18 Mar 2022
- EuBiologics (206650 KS): Cashing on Vaccine Business13 Oct 2021
x